Home » Medical Devices » Amyloidosis Therapeutic Treatment Market

Amyloidosis Therapeutic Treatment Market By Type of Amyloidosis (AL Amyloidosis [Primary Amyloidosis], ATTR Amyloidosis [Hereditary and Wild-Type], AA Amyloidosis [Secondary Amyloidosis]); By Treatment Modalities (Chemotherapy, Immunomodulatory Drugs [IMiDs], Monoclonal Antibodies, TTR Stabilizers, RNA Interference [RNAi] Therapies, Liver Transplantation, Supportive Care); By Disease Severity (Newly Diagnosed Patients, Relapsed or Refractory Disease, Advanced Disease); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Amyloidosis Therapeutic Treatment Market Size 2023	USD 2251.2 Million
Amyloidosis Therapeutic Treatment Market, CAGR	7.60%
Amyloidosis Therapeutic Treatment Market Size 2032	USD 4352.35 Million

Market Insights

Between 2024 and 2032, the global amyloidosis therapeutic treatment market is expected to develop at a compound annual growth rate (CAGR) of 7.60%, from its estimated USD 2251.2 million in 2023 to USD 4352.35 million in 2032.
The significant type of amyloidosis category is AL amyloidosis (primary amyloidosis). On the other hand, ATTR amyloidosis (hereditary and wild-type) is expected to grow at a strong CAGR.
Chemotherapy is anticipated to have the highest compound annual growth rate during the forecast period.
The CAGR for newly diagnosed patients is expected to be the highest during the projection period.
North America dominated the amyloidosis therapeutic treatment market.
Regarding the market share of amyloidosis therapeutic treatment, Europe is expected to come second.
Asia Pacific is anticipated to grow fastest in the amyloidosis therapeutic treatment market.
The primary drivers of the market are the identification of trustworthy biomarkers for early detection and surveillance, the identification of the genetic variables influencing the development of amyloidosis, and the development of imaging techniques for improved disease visualization.
The market is growing due to developments in gene editing technologies such as CRISPR, which are used to target and correct genetic mutations linked to amyloidosis. Additionally, research into immunotherapeutic approaches is being conducted more extensively.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Executive Summary

Market Definition

The formation of amyloids, or protein aggregates, that fold incorrectly and accumulate in different organs is the hallmark of a rare group of disorders known as amyloidosis. The gastrointestinal tract, soft tissue, liver, kidneys, and heart are the organs most commonly impacted. This is an incredibly rare metabolic disorder that affects the structure and function of organs and tissues, potentially leading to fatal illnesses; when amyloid protein accumulates in tissues and organs, a disorder known as amyloidosis develops.

Market Overview

The amyloidosis therapeutic treatment sector is estimated to develop at a 7.60% compound annual growth rate (CAGR) between 2024 and 2032, maintaining its current upward trend. The market will keep developing, rising from its estimated value of USD 2251.2 million in 2023 to USD 4352.35 million in 2032.

Research and development initiatives help scientists better understand the basic mechanics of amyloidosis, including the discovery of specific proteins involved in forming amyloid deposits. This information is crucial for creating tailored treatments that can halt the progression of the illness. Research aims to find biomarkers for amyloidosis, which are quantifiable signs of the disease’s occurrence or progression. Biomarkers can help with early diagnosis, tracking the course of a disease, and determining how well a treatment works. These findings may lead to developing sophisticated diagnostic instruments, enabling prompt intervention. The ongoing advancements in drug discovery technologies enable scientists to find and create new compounds targeting amyloidosis-related pathways. This includes creating therapeutic agents such as antibodies and small molecules that can influence or prevent the buildup of amyloid deposits.

Additionally, developments in molecular biology and genetics aid in identifying genetic variables and mutations linked to various forms of amyloidosis. This information helps to improve therapeutic outcomes by enabling the development of customized treatments based on particular genetic profiles. Progress in R&D adds to the scientific data that regulatory bodies need to assess and authorize novel therapies. Together, researchers and regulatory agencies can expedite the approval process and the delivery of effective therapies to patients.

Segmentation by Type of Amyloidosis

AL amyloidosis (primary amyloidosis) is the market leader by type of amyloidosis. Particularly, amyloid fibrils originating from aberrant immunoglobulin light chains (AL) generated by bone marrow-derived plasma cells are deposited in AL amyloidosis. One subset of white blood cells called plasma cells is responsible for the immune system’s production of antibodies.
The ATTR amyloidosis (hereditary and wild-type) category will exhibit a sizable CAGR during the projected period. The abnormal buildup of amyloid proteins in different body tissues and organs is the hallmark of a rare group of diseases called amyloidosis. One particular kind of amyloidosis involving the accumulation of transthyretin protein is ATTR (transthyretin) amyloidosis.
Another type of amyloidosis, such as AA amyloidosis (secondary amyloidosis), also contributes to the market demand for therapeutic amyloidosis treatment.

Segmentation by Treatment Modalities

Chemotherapy is more popular in the amyloidosis therapeutic treatment market. One of the therapeutic approaches used to treat amyloidosis is chemotherapy. A set of uncommon illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different body tissues and organs.
The immunomodulatory drugs (IMiDs) category will likely register a significant CAGR during forecasting. Because of their anti-inflammatory qualities, IMiDs can help regulate the immune response, especially regarding inflammatory cytokine production.
Monoclonal antibodies, TTR stabilizers, RNA interference (RNAi) therapies, liver transplantation, and supportive care also contribute to the demand for amyloidosis therapeutic treatment market.

Segmentation by Disease Severity

The newly diagnosed patients category is projected to grow at the fastest rate over the projection period. A collection of uncommon illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different organs and tissues. The goals of therapeutic interventions for recently diagnosed amyloidosis patients are to control symptoms, reduce the rate of disease progression, and enhance overall quality of life.
Other disease severity, including relapsed or refractory disease and advanced disease, also influence the need for the amyloidosis therapeutic treatment market.

Segmentation by Region

North America dominates the market for amyloidosis therapeutic treatment. This is brought on by the ongoing research and development of increasingly sophisticated amyloidosis treatment medications, as well as an increase in the population’s genetic susceptibility to the disease.
Europe is estimated to rank second in market size for amyloidosis therapeutic treatment.
The amyloidosis therapeutic treatment industry is predicted to flourish rapidly in Asia.
The remaining requirement for amyloidosis therapeutic treatment is covered by world regions such as Africa, the Middle East, and Latin America.

The market for amyloidosis therapeutic treatment is believed to be significantly influenced by the growing elderly population for several interrelated reasons. A disorder called amyloidosis is defined by an abnormal buildup of amyloid proteins in tissues and organs. The risk of developing amyloidosis rises with age, so an important target market for this market is the elderly population. Diagnoses of amyloidosis are more common in older people. The likelihood of developing diseases linked to amyloidosis, such as Alzheimer’s disease or systemic amyloidosis, rises with age. This increased incidence among older people directly impacts the need for treatments.

Based on projections, North America holds a significant market share of over 65%. North America is dominant worldwide due to a developed healthcare ecosystem and rising awareness of amyloidosis. The demand for amyloidosis treatments is expected to be highest in the United States in North America due to the country’s large investments in medical research and development and the expanding availability of innovative treatments. With first-rate hospitals, academic institutions, and clinical trial capabilities, North America has a sophisticated and well-established healthcare infrastructure. The availability of state-of-the-art technologies and knowledgeable medical personnel facilitates the quick development and uptake of amyloidosis treatment options.

The amyloidosis therapeutic treatment market in Asia Pacific will expand fastest throughout the forecast. Economic growth has increased Population disposable income in many Asia Pacific countries. People can now afford to spend more on healthcare, including treating uncommon illnesses like amyloidosis. The expanding middle class is an important factor driving demand for sophisticated, pricy therapeutic treatments. The governments of the Asia-Pacific area are proactively addressing the difficulties encountered by patients with rare diseases. This involves putting laws and programs in place to help people who suffer from uncommon illnesses like amyloidosis. Government funding priorities for research, development, and access to cutting-edge therapies are making it more favorable for pharmaceutical companies to invest in developing treatments for amyloidosis.

Key Highlights of the Report

The global amyloidosis therapeutic treatment market is segmented by type of amyloidosis, treatment modalities, disease severity, and region. Regarding the type of amyloidosis, AL amyloidosis (primary amyloidosis) is the market spearhead. Chemotherapy is a significant category. The newly diagnosed patients category is anticipated to increase at the highest CAGR throughout the projection period. The amyloidosis therapeutic treatment market is expanding mostly in North America.

The disease’s rising prevalence largely drives the market for amyloidosis therapeutic treatment. A collection of uncommon and complicated illnesses known as amyloidosis is defined by an aberrant buildup of amyloid proteins in different organs and tissues. Several factors cause the increasing incidence of amyloidosis. Dietary practices, lifestyle modifications, and general health trends can influence the incidence of amyloidosis. Amyloidosis is more common because of a possible rise in the prevalence of conditions that make people more susceptible to the disease as global health patterns change. Although amyloidosis is thought to be a rare disease, precise prevalence estimates are difficult due to the disease’s complexity and variety of forms.

The North American region is expected to account for the largest amyloidosis therapeutic treatment market globally. Policy initiatives, including expedited approval procedures, tax breaks for pharmaceutical firms, and research grants, have encouraged capital to be invested in creating treatments for uncommon diseases like amyloidosis. The Asia Pacific is also assumed to have the market’s sharpest growth. Governments throughout the Asia-Pacific area are realizing more and more how critical it is to assist patients suffering from uncommon illnesses like amyloidosis. As a result, initiatives to offer financial support, enhance access to healthcare services, and finance research into more effective treatments for these conditions have been launched.

Which Key Factors Are Driving The Global Amyloidosis Therapeutic Treatment Market?

The main factors driving the market for amyloidosis therapeutic treatment are understanding the prevalence and distribution of the disease, examining the effectiveness of combining different therapeutic approaches, and advancements in drug discovery technologies like high-throughput screening.

What Are The Main Challenges Confronting The Amyloidosis Therapeutic Treatment Market Globally?

The primary barriers impeding the global amyloidosis therapeutic treatment industry are the need for sufficient knowledge regarding the underlying molecular mechanisms and pathophysiology and the commercial community’s limited interest in creating treatments for uncommon diseases.

What Market Opportunities Exist For Amyloidosis Therapeutic Treatment Globally?

The potential for the amyloidosis therapeutic treatment market is driven by the investigation of enzyme replacement to address enzymatic deficiencies associated with specific types of amyloidosis and the use of nanotechnology for targeted drug delivery to specific tissues affected by amyloidosis.

Market Drivers

Multiple factors propel the amyloidosis therapeutic treatment industry across the globe. The primary factors propelling the global amyloidosis therapeutic treatment market are as follows:

Increasing Global Population of Elderly Individuals

During the projection period, an increase in transthyretin amyloidosis incidence is anticipated due to the nation’s aging population. Based on NCBI data, wild-type ATTR, another name for an age-related form of amyloidosis, is primarily heart-related. In 2020, about 727 million people in the world were 65 years of age or older. By 2050, there will likely be 1.5 billion senior people worldwide, expanding at a 16.0% annual pace. This factor aids market expansion. Multiple comorbidities are common in older people, which complicates the management of amyloidosis. The co-existence of additional medical conditions could make treatment more difficult and necessitate specialized therapeutic approaches that deal with both amyloidosis and other age-related health problems. Older adults frequently need more resources and services in the healthcare system. Because older adults are more likely to have amyloidosis, there is a greater need for treatments to effectively manage and treat the disease, which drives up healthcare facility utilization.

Market Restraints

There are several obstacles that the global amyloidosis therapeutic treatment market must overcome to continue growing. Among them are the following:

Complexity of Illness and its Identification

The primary reason impeding the market expansion for amyloidosis therapeutic treatments is the disease’s intricacy, both in terms of the illness itself and the diagnostic procedures. The inappropriate buildup of amyloid proteins in multiple organs indicates a rare set of disorders collectively known as amyloidosis. Distinct organ systems are affected by distinct forms of amyloidosis, each connecting to particular proteins. Establishing a therapy technique that works for everyone is difficult due to this variety. Amyloidosis symptoms might cross over into other, more prevalent conditions. This overlap can result in delayed or incorrect diagnoses, preventing patients from getting the right care when needed. This factor will restrain the development of the amyloidosis therapeutic treatment market.

Opportunities

There are plenty of potential prospects in the global amyloidosis therapeutic treatment industry. Among these are the following:

Increase In The Number Of Government Initiatives

Numerous programs launched by governmental and non-governmental organizations to raise public awareness of the illness and the advantages of treatment are expected to increase early diagnosis and treatment rates. To raise awareness of the disease among several medical professionals and ATTR amyloidosis patients, the Australian Amyloidosis Network, for example, arranged a biennial touring workshop in May 2021. The objective was to help patients and doctors comprehend the complexities of the disease, which will aid in the creation of novel treatments for transthyretin amyloidosis. Since amyloidosis is frequently regarded as a rare disease, some governments may designate certain drugs as orphan drugs. Pharmaceutical companies may be encouraged to invest in developing rare condition therapies due to this designation, which may result in regulatory incentives such as reduced fees and extended market exclusivity. Governments may make investments to upgrade the healthcare infrastructure, including specialized clinics and facilities for identifying and managing uncommon illnesses like amyloidosis. Expanded access to treatments is made possible by improved infrastructure.

Competitive Landscape

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Players

Several major competitors exist in the fiercely competitive global amyloidosis therapeutic treatment market. The following are a few of the leading market participants and their market shares:

Prothena Corporation Plc.
Eidos Therapeutics
Pfizer Inc.
SOM Biotech
Corino Therapeutics
Johnson and Johnson Services, Inc.
AstraZeneca Plc.
Alnylam Pharmaceuticals, Inc.
GlaxoSmithKline, Plc.
Others

To remain competitive, these companies prioritize product innovation, distribution channel expansion, mergers, and acquisitions.

The largest suppliers in the global amyloidosis therapeutic treatment market continuously work to keep one step ahead of the competition by developing innovative concepts and products.

In February 2023, Dicerna Pharmaceuticals purchased Entos Pharmaceuticals, a clinical-stage biopharmaceutical business offering RNA interference (RNAi) therapeutics for amyloidosis. This acquisition expanded Dicerna’s therapy options for amyloidosis.

In January 2023, Astellas Pharma purchased Swiss biopharmaceutical company Polyphor International, which specializes in treating amyloidosis. Astellas aimed to advance the development of PPH20, a small molecule that inhibits the formation of amyloid fibrils, and strengthen its position in the amyloidosis market.

Summary of Key Findings

The market for amyloidosis therapeutic treatment continues to be influenced by a growing continuous innovation and development of advanced technologies.
The market is segmented by type of amyloidosis, treatment modalities, disease severity, and region.
The market’s most popular type of amyloidosis is AL amyloidosis (primary amyloidosis).
Chemotherapy is the foremost category.
Newly diagnosed patients are expected to grow fastest regarding CAGR during the forecast period.
North America is leading market development; the market is highly competitive with key players including Prothena Corporation Plc., Eidos Therapeutics, Pfizer Inc., SOM Biotech, Corino Therapeutics, Johnson and Johnson Services, Inc., AstraZeneca Plc., Alnylam Pharmaceuticals, Inc., GlaxoSmithKline, Plc., and Others.

Future Outlook

The amyloidosis therapeutic treatment industry is expected to increase significantly in North America and has a positive outlook worldwide.
The developments in utilizing machine learning for drug discovery support expanding the global market.
A lack of awareness will hinder the market’s growth for amyloidosis therapeutic treatment during the anticipated period.
To stay ahead of the competition, key enterprises must develop new products, expand their market reach, and keep their prices competitive.

How CXOs Can Benefit from the Credence Research Amyloidosis Therapeutic Treatment Market Report

CXOs may get a detailed picture of the market in the Credence Research Amyloidosis Therapeutic Treatment Market Report, which includes:

Market size and growth forecast: The report provides detailed estimates of the global amyloidosis therapeutic treatment market size, segmented by type of amyloidosis, treatment modalities, disease severity, and region. It also includes forecasts for the market through 2032 based on key trends and drivers.
Market segmentation: The research report breaks down the market for amyloidosis therapeutic treatment into segments based on the type of amyloidosis, treatment modalities, disease severity, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
Competitive landscape: The research report offers a detailed analysis of the major companies in the amyloidosis therapeutic treatment industry, including information on their business plans, line of products, and earnings. CXOs can use this information to evaluate and identify their competitors.
Key trends and drivers: The research report identifies and evaluates the main trends and factors influencing the market for amyloidosis therapeutic treatment. CXOs can use this information to make well-informed choices regarding their plans and investments.

CXOs can use the insights from the Credence Research Amyloidosis Therapeutic Treatment Market Report to:

Identify growth opportunities: With the help of this analysis, CXOs may identify new growth opportunities in the amyloidosis therapeutic treatment sector. For example, the report identifies the growing demand for amyloidosis therapeutic treatment from newly diagnosed patients as a key opportunity.
Make informed investment decisions: With the help of the report, CXOs can choose amyloidosis treatment wisely. For example, the research study provides information on the critical factors to consider while selecting amyloidosis treatment solutions and evaluating amyloidosis treatment suppliers.
Develop competitive strategies: The research report can be used by CXOs to develop competitive strategies for their amyloidosis treatment businesses. For example, the research paper outlines the main strategies suppliers of amyloidosis therapeutic treatment utilize to differentiate themselves from competitors.
Track market developments: CXOs may stay ahead of the curve by tracking market developments with the aid of this research report. For instance, the research report offers insights into the most recent developments and trends in the market for amyloidosis therapeutic treatment.

CXOs seeking to expand their industry knowledge and spot growth prospects will find the Credence Research Amyloidosis Therapeutic Treatment Market Report a useful tool.

Segmentation

By Type of Amyloidosis
- AL Amyloidosis (Primary Amyloidosis)
- ATTR Amyloidosis (Hereditary and Wild-Type)
- AA Amyloidosis (Secondary Amyloidosis)
By Treatment Modalities
- Chemotherapy
- Immunomodulatory Drugs (IMiDs)
- Monoclonal Antibodies
- TTR Stabilizers
- RNA Interference (RNAi) Therapies
- Liver Transplantation
- Supportive Care
By Disease Severity
- Newly Diagnosed Patients
- Relapsed or Refractory Disease
- Advanced Disease
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Amyloidosis Therapeutic Treatment Market
2.1.1. Global Amyloidosis Therapeutic Treatment Market, By Type of Amyloidosis
2.1.2. Global Amyloidosis Therapeutic Treatment Market, By Treatment Modalities
2.1.3. Global Amyloidosis Therapeutic Treatment Market, By Disease Severity
2.1.4. Global Amyloidosis Therapeutic Treatment Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Amyloidosis Therapeutic Treatment Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Amyloidosis Therapeutic Treatment Market Drivers
3.2.2. Amyloidosis Therapeutic Treatment Market Restraints
3.2.3. Amyloidosis Therapeutic Treatment Market Opportunities
3.2.4. Major Amyloidosis Therapeutic Treatment Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type of Amyloidosis
3.5.2. Treatment Modalities
3.5.3. Disease Severity
3.5.4. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Amyloidosis Therapeutic Treatment Market: Company Market Share, Value 2023
4.1.2. Global Amyloidosis Therapeutic Treatment Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Amyloidosis Therapeutic Treatment Market: Top 3 Company Market Share, Value 2023
4.2. Global Amyloidosis Therapeutic Treatment Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Amyloidosis Therapeutic Treatment Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Amyloidosis Therapeutic Treatment Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Amyloidosis Therapeutic Treatment Market, By Type of Amyloidosis
8.1. Global Amyloidosis Therapeutic Treatment Market Overview, by Type of Amyloidosis
8.1.1. Global Amyloidosis Therapeutic Treatment Market Revenue Share, By Type of Amyloidosis, 2023 Vs 2032 (in %)
8.2. AL Amyloidosis (Primary Amyloidosis)
8.2.1. Global Amyloidosis Therapeutic Treatment Market, By AL Amyloidosis (Primary Amyloidosis), By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for AL Amyloidosis (Primary Amyloidosis)
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. ATTR Amyloidosis (Hereditary and Wild-Type)
8.3.1. Global Amyloidosis Therapeutic Treatment Market, By ATTR Amyloidosis (Hereditary and Wild-Type), By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for ATTR Amyloidosis (Hereditary and Wild-Type)
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. AA Amyloidosis (Secondary Amyloidosis)
8.4.1. Global Amyloidosis Therapeutic Treatment Market, By AA Amyloidosis (Secondary Amyloidosis), By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for AA Amyloidosis (Secondary Amyloidosis)
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
9. Global Amyloidosis Therapeutic Treatment Market, By Treatment Modalities
9.1. Global Amyloidosis Therapeutic Treatment Market Overview, by Treatment Modalities
9.1.1. Global Amyloidosis Therapeutic Treatment Market Revenue Share, By Treatment Modalities, 2023 Vs 2032 (in %)
9.2. Chemotherapy
9.2.1. Global Amyloidosis Therapeutic Treatment Market, By Chemotherapy, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Chemotherapy
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Immunomodulatory Drugs (IMiDs)
9.3.1. Global Amyloidosis Therapeutic Treatment Market, By Immunomodulatory Drugs (IMiDs), By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Immunomodulatory Drugs (IMiDs)
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Monoclonal Antibodies
9.4.1. Global Amyloidosis Therapeutic Treatment Market, By Monoclonal Antibodies, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Monoclonal Antibodies
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. TTR Stabilizers
9.5.1. Global Amyloidosis Therapeutic Treatment Market, By TTR Stabilizers, By Region, 2019-2032 (US$ Mn)
9.5.2. Market Dynamics for TTR Stabilizers
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
9.6. RNA Interference (RNAi) Therapies
9.6.1. Global Amyloidosis Therapeutic Treatment Market, By RNA Interference (RNAi) Therapies, By Region, 2019-2032 (US$ Mn)
9.6.2. Market Dynamics for RNA Interference (RNAi) Therapies
9.6.2.1. Drivers
9.6.2.2. Restraints
9.6.2.3. Opportunities
9.6.2.4. Trends
9.7. Liver Transplantation
9.7.1. Global Amyloidosis Therapeutic Treatment Market, By Liver Transplantation, By Region, 2019-2032 (US$ Mn)
9.7.2. Market Dynamics for Liver Transplantation
9.7.2.1. Drivers
9.7.2.2. Restraints
9.7.2.3. Opportunities
9.7.2.4. Trends
9.8. Supportive Care
9.8.1. Global Amyloidosis Therapeutic Treatment Market, By Supportive Care, By Region, 2019-2032 (US$ Mn)
9.8.2. Market Dynamics for Supportive Care
9.8.2.1. Drivers
9.8.2.2. Restraints
9.8.2.3. Opportunities
9.8.2.4. Trends
10. Global Amyloidosis Therapeutic Treatment Market, By Disease Severity
10.1. Global Amyloidosis Therapeutic Treatment Market Overview, by Disease Severity
10.1.1. Global Amyloidosis Therapeutic Treatment Market Revenue Share, By Disease Severity, 2023 Vs 2032 (in %)
10.2. Newly Diagnosed Patients
10.2.1. Global Amyloidosis Therapeutic Treatment Market, By Newly Diagnosed Patients, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Newly Diagnosed Patients
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Relapsed or Refractory Disease
10.3.1. Global Amyloidosis Therapeutic Treatment Market, By Relapsed or Refractory Disease, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Relapsed or Refractory Disease
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Advanced Disease
10.4.1. Global Amyloidosis Therapeutic Treatment Market, By Advanced Disease, By Region, 2019-2032 (US$ Mn)
10.4.2. Market Dynamics for Advanced Disease
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
11. Global Amyloidosis Therapeutic Treatment Market, By Region
11.1. Global Amyloidosis Therapeutic Treatment Market Overview, by Region
11.1.1. Global Amyloidosis Therapeutic Treatment Market, By Region, 2023 Vs 2032 (in%)
11.2. Type of Amyloidosis
11.2.1. Global Amyloidosis Therapeutic Treatment Market, By Type of Amyloidosis, 2019-2032 (US$ Mn)
11.3. Treatment Modalities
11.3.1. Global Amyloidosis Therapeutic Treatment Market, By Treatment Modalities, 2019-2032 (US$ Mn)
11.4. Disease Severity
11.4.1. Global Amyloidosis Therapeutic Treatment Market, By Disease Severity, 2019-2032 (US$ Mn)
12. North America Amyloidosis Therapeutic Treatment Market Analysis
12.1. Overview
12.1.1. Market Dynamics for North America
12.1.1.1. Drivers
12.1.1.2. Restraints
12.1.1.3. Opportunities
12.1.1.4. Trends
12.2. North America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
12.5.1. North America Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
12.5.2. U.S.
12.5.3. Canada
12.5.4. Mexico
13. Europe Amyloidosis Therapeutic Treatment Market Analysis
13.1. Overview
13.1.1. Market Dynamics for Europe
13.1.1.1. Drivers
13.1.1.2. Restraints
13.1.1.3. Opportunities
13.1.1.4. Trends
13.2. Europe Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
13.5.1. Europe Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
13.5.2. UK
13.5.3. France
13.5.4. Germany
13.5.5. Italy
13.5.6. Spain
13.5.7. Benelux
13.5.8. Russia
13.5.9. Rest of Europe
14. Asia Pacific Amyloidosis Therapeutic Treatment Market Analysis
14.1. Overview
14.1.1. Market Dynamics for Asia Pacific
14.1.1.1. Drivers
14.1.1.2. Restraints
14.1.1.3. Opportunities
14.1.1.4. Trends
14.2. Asia Pacific Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
14.5.1. Asia Pacific Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
14.5.2. China
14.5.3. Japan
14.5.4. India
14.5.5. South Korea
14.5.6. South East Asia
14.5.7. Rest of Asia Pacific
15. Latin America Amyloidosis Therapeutic Treatment Market Analysis
15.1. Overview
15.1.1. Market Dynamics for Latin America
15.1.1.1. Drivers
15.1.1.2. Restraints
15.1.1.3. Opportunities
15.1.1.4. Trends
15.2. Latin America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
15.5.1. Latin America Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
15.5.2. Brazil
15.5.3. Argentina
15.5.4. Rest of Latin America
16. Middle East Amyloidosis Therapeutic Treatment Market Analysis
16.1. Overview
16.1.1. Market Dynamics for Middle East
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. Middle East Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
16.5.1. Middle East Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
16.5.2. UAE
16.5.3. Saudi Arabia
16.5.4. Rest of Middle East
17. Africa Amyloidosis Therapeutic Treatment Market Analysis
17.1. Overview
17.1.1. Market Dynamics for Africa
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Africa Amyloidosis Therapeutic Treatment Market, by Country, 2019-2032 (US$ Mn)
17.5.1. Africa Amyloidosis Therapeutic Treatment Market, by Country, 2023 Vs 2032 (in%)
17.5.2. South Africa
17.5.3. Egypt
17.5.4. Rest of Africa
18. Company Profiles
18.1. Prothena Corporation Plc.
18.1.1. Company Overview
18.1.2. Products/Services Portfolio
18.1.3. Geographical Presence
18.1.4. SWOT Analysis
18.1.5. Financial Summary
18.1.5.1. Market Revenue and Net Profit (2019-2023)
18.1.5.2. Business Segment Revenue Analysis
18.1.5.3. Geographical Revenue Analysis
18.2. Eidos Therapeutics
18.3. Pfizer Inc.
18.4. SOM Biotech
18.5. Corino Therapeutics
18.6. Johnson and Johnson Services, Inc.
18.7. AstraZeneca Plc.
18.8. Alnylam Pharmaceuticals, Inc.
18.9. GlaxoSmithKline, Plc.
19. Research Methodology
19.1. Research Methodology
19.2. Phase I – Secondary Research
19.3. Phase II – Data Modelling
19.3.1. Company Share Analysis Model
19.3.2. Revenue Based Modelling
19.4. Phase III – Primary Research
19.5. Research Limitations
19.5.1. Assumptions

List of Figures
FIG. 1 Global Amyloidosis Therapeutic Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Amyloidosis Therapeutic Treatment Market Segmentation
FIG. 4 Global Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2023 (US$ Mn)
FIG. 5 Global Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2023 (US$ Mn)
FIG. 6 Global Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2023 (US$ Mn)
FIG. 7 Global Amyloidosis Therapeutic Treatment Market, by Geography, 2023 (US$ Mn)
FIG. 8 Attractive Investment Proposition, by Type of Amyloidosis, 2023
FIG. 9 Attractive Investment Proposition, by Treatment Modalities, 2023
FIG. 10 Attractive Investment Proposition, by Disease Severity, 2023
FIG. 11 Attractive Investment Proposition, by Geography, 2023
FIG. 12 Global Market Share Analysis of Key Amyloidosis Therapeutic Treatment Market Manufacturers, 2023
FIG. 13 Global Market Positioning of Key Amyloidosis Therapeutic Treatment Market Manufacturers, 2023
FIG. 14 Global Amyloidosis Therapeutic Treatment Market Value Contribution, By Type of Amyloidosis, 2023 & 2032 (Value %)
FIG. 15 Global Amyloidosis Therapeutic Treatment Market, by AL Amyloidosis (Primary Amyloidosis), Value, 2019-2032 (US$ Mn)
FIG. 16 Global Amyloidosis Therapeutic Treatment Market, by ATTR Amyloidosis (Hereditary and Wild-Type), Value, 2019-2032 (US$ Mn)
FIG. 17 Global Amyloidosis Therapeutic Treatment Market, by AA Amyloidosis (Secondary Amyloidosis), Value, 2019-2032 (US$ Mn)
FIG. 18 Global Amyloidosis Therapeutic Treatment Market Value Contribution, By Treatment Modalities, 2023 & 2032 (Value %)
FIG. 19 Global Amyloidosis Therapeutic Treatment Market, by Chemotherapy, Value, 2019-2032 (US$ Mn)
FIG. 20 Global Amyloidosis Therapeutic Treatment Market, by Immunomodulatory Drugs (IMiDs), Value, 2019-2032 (US$ Mn)
FIG. 21 Global Amyloidosis Therapeutic Treatment Market, by Monoclonal Antibodies, Value, 2019-2032 (US$ Mn)
FIG. 22 Global Amyloidosis Therapeutic Treatment Market, by TTR Stabilizers, Value, 2019-2032 (US$ Mn)
FIG. 23 Global Amyloidosis Therapeutic Treatment Market, by RNA Interference (RNAi) Therapies, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Amyloidosis Therapeutic Treatment Market, by Liver Transplantation, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Amyloidosis Therapeutic Treatment Market, by Supportive Care, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Amyloidosis Therapeutic Treatment Market Value Contribution, By Disease Severity, 2023 & 2032 (Value %)
FIG. 27 Global Amyloidosis Therapeutic Treatment Market, by Newly Diagnosed Patients, Value, 2019-2032 (US$ Mn)
FIG. 28 Global Amyloidosis Therapeutic Treatment Market, by Relapsed or Refractory Disease, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Amyloidosis Therapeutic Treatment Market, by Advanced Disease, Value, 2019-2032 (US$ Mn)
FIG. 30 North America Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 31 U.S. Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 32 Canada Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 33 Mexico Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 34 Europe Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 35 Germany Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 36 France Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 37 U.K. Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 38 Italy Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 39 Spain Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 40 Benelux Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 41 Russia Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 42 Rest of Europe Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 43 Asia Pacific Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 44 China Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 45 Japan Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 46 India Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 47 South Korea Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 48 South-East Asia Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 49 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 50 Latin America Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 51 Brazil Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 52 Argentina Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 53 Rest of Latin America Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 54 Middle East Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 55 UAE Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 56 Saudi Arabia Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 57 Rest of Middle East Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 58 Africa Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 59 South Africa Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 60 Egypt Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)
FIG. 61 Rest of Africa Amyloidosis Therapeutic Treatment Market, 2019-2032 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Amyloidosis Therapeutic Treatment Market
TABLE 2 Global Amyloidosis Therapeutic Treatment Market: Market Drivers Impact Analysis
TABLE 3 Global Amyloidosis Therapeutic Treatment Market: Market Restraints Impact Analysis
TABLE 4 Global Amyloidosis Therapeutic Treatment Market, by Competitive Benchmarking, 2023
TABLE 5 Global Amyloidosis Therapeutic Treatment Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Amyloidosis Therapeutic Treatment Market, by Key Strategies Analysis, 2023
TABLE 7 Global Amyloidosis Therapeutic Treatment Market, by AL Amyloidosis (Primary Amyloidosis), By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Amyloidosis Therapeutic Treatment Market, by AL Amyloidosis (Primary Amyloidosis), By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Amyloidosis Therapeutic Treatment Market, by ATTR Amyloidosis (Hereditary and Wild-Type), By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Amyloidosis Therapeutic Treatment Market, by ATTR Amyloidosis (Hereditary and Wild-Type), By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Amyloidosis Therapeutic Treatment Market, by AA Amyloidosis (Secondary Amyloidosis), By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Amyloidosis Therapeutic Treatment Market, by AA Amyloidosis (Secondary Amyloidosis), By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Amyloidosis Therapeutic Treatment Market, by Chemotherapy, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Amyloidosis Therapeutic Treatment Market, by Chemotherapy, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Amyloidosis Therapeutic Treatment Market, by Immunomodulatory Drugs (IMiDs), By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Amyloidosis Therapeutic Treatment Market, by Immunomodulatory Drugs (IMiDs), By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Amyloidosis Therapeutic Treatment Market, by Monoclonal Antibodies, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Amyloidosis Therapeutic Treatment Market, by Monoclonal Antibodies, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Amyloidosis Therapeutic Treatment Market, by TTR Stabilizers, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Amyloidosis Therapeutic Treatment Market, by TTR Stabilizers, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Amyloidosis Therapeutic Treatment Market, by RNA Interference (RNAi) Therapies, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Amyloidosis Therapeutic Treatment Market, by RNA Interference (RNAi) Therapies, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Amyloidosis Therapeutic Treatment Market, by Liver Transplantation, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Amyloidosis Therapeutic Treatment Market, by Liver Transplantation, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Amyloidosis Therapeutic Treatment Market, by Supportive Care, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Amyloidosis Therapeutic Treatment Market, by Supportive Care, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Amyloidosis Therapeutic Treatment Market, by Newly Diagnosed Patients, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Amyloidosis Therapeutic Treatment Market, by Newly Diagnosed Patients, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Amyloidosis Therapeutic Treatment Market, by Relapsed or Refractory Disease, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Amyloidosis Therapeutic Treatment Market, by Relapsed or Refractory Disease, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Amyloidosis Therapeutic Treatment Market, by Advanced Disease, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Amyloidosis Therapeutic Treatment Market, by Advanced Disease, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 34 Global Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 35 Global Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 36 Global Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 37 Global Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 38 Global Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 39 Global Amyloidosis Therapeutic Treatment Market, by Region, 2019-2023 (US$ Mn)
TABLE 40 Global Amyloidosis Therapeutic Treatment Market, by Region, 2024-2032 (US$ Mn)
TABLE 41 North America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 42 North America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 43 North America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 44 North America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 45 North America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 46 North America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 47 North America Amyloidosis Therapeutic Treatment Market, by Country, 2019-2023 (US$ Mn)
TABLE 48 North America Amyloidosis Therapeutic Treatment Market, by Country, 2024-2032 (US$ Mn)
TABLE 49 United States Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 50 United States Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 51 United States Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 52 United States Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 53 United States Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 54 United States Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 55 Canada Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 56 Canada Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 57 Canada Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 58 Canada Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 59 Canada Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 60 Canada Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 61 Mexico Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 62 Mexico Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 63 Mexico Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 64 Mexico Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 65 Mexico Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 66 Mexico Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 67 Europe Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 68 Europe Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 69 Europe Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 70 Europe Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 71 Europe Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 72 Europe Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 73 Europe Amyloidosis Therapeutic Treatment Market, by Country, 2019-2023 (US$ Mn)
TABLE 74 Europe Amyloidosis Therapeutic Treatment Market, by Country, 2024-2032 (US$ Mn)
TABLE 75 Germany Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 76 Germany Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 77 Germany Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 78 Germany Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 79 Germany Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 80 Germany Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 81 France Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 82 France Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 83 France Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 84 France Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 85 France Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 86 France Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 87 United Kingdom Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 88 United Kingdom Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 89 United Kingdom Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 90 United Kingdom Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 91 United Kingdom Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 92 United Kingdom Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 93 Italy Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 94 Italy Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 95 Italy Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 96 Italy Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 97 Italy Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 98 Italy Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 99 Spain Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 100 Spain Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 101 Spain Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 102 Spain Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 103 Spain Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 104 Spain Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 105 Benelux Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 106 Benelux Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 107 Benelux Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 108 Benelux Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 109 Benelux Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 110 Benelux Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 111 Russia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 112 Russia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 113 Russia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 114 Russia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 115 Russia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 116 Russia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 117 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 118 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 119 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 120 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 121 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 122 Rest of Europe Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 123 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 124 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 125 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 126 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 127 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 128 Asia Pacific Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 129 China Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 130 China Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 131 China Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 132 China Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 133 China Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 134 China Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 135 Japan Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 136 Japan Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 137 Japan Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 138 Japan Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 139 Japan Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 140 Japan Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 141 India Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 142 India Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 143 India Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 144 India Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 145 India Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 146 India Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 147 South Korea Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 148 South Korea Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 149 South Korea Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 150 South Korea Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 151 South Korea Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 152 South Korea Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 153 South-East Asia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 154 South-East Asia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 155 South-East Asia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 156 South-East Asia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 157 South-East Asia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 158 South-East Asia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 159 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 160 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 161 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 162 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 163 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 164 Rest of Asia Pacific Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 165 Latin America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 166 Latin America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 167 Latin America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 168 Latin America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 169 Latin America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 170 Latin America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 171 Brazil Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 172 Brazil Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 173 Brazil Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 174 Brazil Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 175 Brazil Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 176 Brazil Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 177 Argentina Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 178 Argentina Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 179 Argentina Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 180 Argentina Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 181 Argentina Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 182 Argentina Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 183 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 184 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 185 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 186 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 187 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 188 Rest of Latin America Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 189 Middle East Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 190 Middle East Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 191 Middle East Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 192 Middle East Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 193 Middle East Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 194 Middle East Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 195 UAE Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 196 UAE Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 197 UAE Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 198 UAE Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 199 UAE Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 200 UAE Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 201 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 202 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 203 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 204 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 205 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 206 Saudi Arabia Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 207 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 208 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 209 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 210 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 211 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 212 Rest of Middle East Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 213 Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 214 Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 215 Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 216 Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 217 Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 218 Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 219 South Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 220 South Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 221 South Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 222 South Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 223 South Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 224 South Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 225 Egypt Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 226 Egypt Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 227 Egypt Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 228 Egypt Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 229 Egypt Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 230 Egypt Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)
TABLE 231 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2019-2023 (US$ Mn)
TABLE 232 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Type of Amyloidosis, 2024-2032 (US$ Mn)
TABLE 233 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2019-2023 (US$ Mn)
TABLE 234 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Treatment Modalities, 2024-2032 (US$ Mn)
TABLE 235 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2019-2023 (US$ Mn)
TABLE 236 Rest of Africa Amyloidosis Therapeutic Treatment Market, by Disease Severity, 2024-2032 (US$ Mn)

Frequently Asked Question:

How much does the global market currently hold for amyloidosis therapeutic treatment?

In 2023, the amyloidosis therapeutic treatment market was estimated to be worth USD 2251.2 million.

What is the market’s projected growth rate of the amyloidosis therapeutic treatment market between 2024 and 2032?

The amyloidosis therapeutic treatment market is anticipated to increase at a CAGR of 7.60% from 2024 to 2032, reaching USD 4352.35 million in 2032.

In terms of the type of amyloidosis, which market category is leading?

AL amyloidosis (primary amyloidosis) is the most popular type.

Regarding the treatment modalities, which market category is in the lead?

The noteworthy treatment modalities segment is chemotherapy.

Who are the main players in the global amyloidosis therapeutic treatment industry?

The top players include Prothena Corporation Plc., Eidos Therapeutics, Pfizer Inc., SOM Biotech, Corino Therapeutics, Johnson and Johnson Services, Inc., AstraZeneca Plc., Alnylam Pharmaceuticals, Inc., GlaxoSmithKline, Plc., and others.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –